PubMed Health⌕ Search

Biomedical subjects

C Raina MacIntyre

Publications and source records attributed to C Raina MacIntyre.

10 recordsLinked to original sources
PubMed2004

Effectiveness of the linkage of child care and maternity payments to childhood immunisation.

In 1998, Australia enacted comprehensive national legislation making receipt of the maternity immunisation allowance (MIA) and the child care benefit (CCB) conditional on evidence of age-appropriate immunisation. We assessed the impact of this policy on immunisation status using a nationally representative population-based case-control study of 589 fully immunised controls and 190 incompletely immunised cases, aged 28-31 months. Immunisation status was significantly associated with parent awareness of the MIA (adjusted odds ratio (aOR) = 3.34, 95% CI = 2.28 - 4.91) and CCB (aOR = 2.08, 95% CI = 1.30 - 3.34). Only 31% of the 219 control parents who were receiving the CCB reported that they could continue to afford child care without the assistance of the CCB. The use of legislated financial immunisation incentives for parents appears to be widely accepted among Australian parents and to have had an impact on immunisation uptake. The policy may serve as a model for other comparable countries.

Australia↗
PubMed2004

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

BACKGROUND: Pneumococcal conjugate vaccine, 7 valent (PCV7) is the most costly vaccine yet considered for publicly funded programs. In mid 2001, Australia funded PCV7 for high-risk groups only (indigenous children and children with certain underlying medical conditions). World wide, non-industry-funded studies and studies using cost-utility measures are sparse. We undertook an independent economic analysis of PCV7 compared with no vaccination in the non high-risk Australian childhood population using cost-utility and cost-effectiveness measures. METHODS: The incidence of invasive pneumococcal disease (IPD), non-bacteraemic pneumonia and otitis media was estimated using representative urban Australian data, or by extrapolation from comparable industrialised countries. A decision-analytic model was developed for a hypothetical birth cohort using the age-specific vaccine coverage from the Californian randomised controlled trial of PCV7. Health outcomes were measured by life-years saved and deaths and disability-adjusted life-years (DALYs) averted. In line with government guidelines, only direct costs were considered in 1997-1998 Australian dollars. RESULTS: For a birth cohort of 250,000, the gross cost of vaccination is $ 78.6 million. Subtracting treatment cost savings, the net cost (discounted) is $ 61.7 million. In undiscounted terms, vaccination prevents 13.7 deaths, 11.2 (82%) from IPD and the remainder from non-bacteraemic pneumonia. The discounted cost per death avoided is $ 5.0 million, per life-year saved $ 230,130 and per DALY averted $ 121,100, giving a break-even vaccine price of $ 15.40 per dose. These estimates are most sensitive to the unit cost per dose of vaccine, estimates of incidence and vaccine efficacy against non-bacteraemic pneumonia and the discount rate. The cost per DALY reduced to $ 81,000 with a discount rate of 3% rather than 5% and to $ 90,000 with the most favourable assumptions concerning pneumonia reduction. DISCUSSION: With a vaccine price of $ 90 per dose, mid-range estimates of impact against non-bacteraemic pneumonia, and discount rate of 5%, a PCV7 program for infants not at high risk of IPD is at the upper limit of cost per DALY previously approved under Australian pharmaceutical funding guidelines. The impact of PCV7 against non-bacteraemic pneumonia is poorly defined, but its importance to cost-effectiveness in resource rich and resource poor settings warrants further studies or analysis to give greater precision to this outcome.

Australia↗
PubMed2004

Reasons for incomplete immunisation among Australian children. A national survey of parents.

BACKGROUND: Incomplete immunisation among Australian children may be due to parents disagreeing with immunisation rather than medical contraindications or access issues. SETTING AND METHODS: The parents of 1338 children recorded on the ACIR as incompletely immunised were telephoned and interviewed. RESULTS: Of the 462 parents who confirmed their child was incompletely immunised, 270 (58%) disagreed with or were concerned about immunisation; 190 (70%) of these were concerned about vaccine side effects. The disagreeing 270 parents were significantly more likely to be highly educated and have a child with no vaccinations recorded on the ACIR. No vaccinations were recorded on the ACIR for 81% of children of both these parents, and of parents registered as conscientious objectors to immunisation. Together these two groups accounts for 2.5-3.0% of the annual birth cohort. DISCUSSION: In order to achieve the 95% immunisation rates necessary for disease control, tailored approaches to promote immunisation among parents are required.

Australia↗
PubMed2003

Measles vaccination coverage among five-year-old children: implications for disease elimination in Australia.

OBJECTIVES: To (i) assess under-reporting of measles-mumps-rubella (MMR) vaccinations to the Australian Childhood Immunisation Register (ACIR); (ii) estimate MMR coverage among five-year-old children and the proportion immune to measles infection; (iii) identify factors related to non-uptake of MMR vaccination. METHODS: We analysed ACIR data for a birth cohort of approximately 64,000 children aged five years. The parents of a sample of 506 children with no ACIR record for the second MMR vaccination (MMR2), due at four years of age, were interviewed by telephone to assess under-reporting to the ACIR and reasons for non-uptake of MMR vaccination. RESULTS: Parents reported that 22% (n = 111) of the surveyed 506 children had received MMR2 before their fifth birthday, and 42% (n = 214) by approximately 5.5 years of age. After correcting for this level of under-reporting to the ACIR, MMR2 coverage for the entire cohort at five years of age was 52.9% (95% CI 52.3-53.4), and increased to 84.1% (95% CI 83.4-84.8) by approximately 5.5 years of age. This was 4.3% and 8.2%, respectively, higher than ACIR coverage estimates at the two ages. Based on the corrected MMR coverage estimates, 93% of the cohort was immune to measles due to vaccination. The most common parent-reported reason for incomplete vaccination was lack of knowledge about the MMR vaccination schedule. CONCLUSIONS: Measles elimination in Australia will require continued effort in vaccination coverage and timeliness among pre-school children. School-entry requirements are important for MMR2 uptake. Strategies are needed to improve reporting to the ACIR for more accurate measurement of coverage.

Attitude to Health↗
PubMed2003

Immunisation coverage in Australia corrected for under-reporting to the Australian Childhood Immunisation Register.

OBJECTIVE: To assess the level of under-reporting to the Australian Childhood Immunisation Register (ACIR) and the resulting underestimation of national immunisation coverage using ACIR data, and to correct national immunisation estimates for under-reporting. METHODS: A national population-based telephone survey was conducted in May-July 2001 of two random samples of children born in 1998 and 1999 who were recorded on the ACIR as incompletely immunised at either 12 months or 24 months of age. Parents were asked whether and when their child had received the vaccinations required to qualify as fully immunised. Survey data were then used to correct ACIR-derived coverage estimates at 12 and 24 months of age. RESULTS: Of 640 surveyed children in the 12-month group, 258 (40%) met the study definition of 'definitely immunised'. This adjusted the ACIR coverage estimate upwards by 2.7% to 94% (95% CI 93.6-94.1). Of 698 surveyed children in the 24-month group, 387 (55%) met the study definition of 'definitely immunised' at the second birthday. Adjusted coverage for doses due by 24 months was 89.8% (95% CI 89.6-90.1), 5% higher than recorded on the ACIR. CONCLUSIONS: Immunisation coverage in Australia for all scheduled vaccines due by 12 months of age is 94% and for all vaccines due by two years of age is almost 90%. The ACIR underestimates coverage by up to 5%. As the ACIR database relies on provider notification, published estimates of immunisation coverage are unlikely to rise significantly above current levels, unless mechanisms are put in place to further improve notification to the ACIR.

Australia↗
PubMed2003

Estimating immunisation coverage: is the 'third dose assumption' still valid?

Immunisation coverage is calculated from Australian Childhood Immunisation Register (ACIR) data using the 'third dose assumption'. This assumes that if the third in a series of vaccine doses has been recorded on the ACIR, the previous two doses have been received, whether or not they are recorded. The objectives of this study were to validate the 'third dose assumption', and measure the impact of the assumption on immunisation coverage estimates at 12 months of age. A sample of children born in 1999 and assessed as fully immunised at 12 months of age by applying the 'third dose assumption' were selected from the ACIR. Parents were interviewed by telephone to obtain information about vaccinations not recorded on the ACIR. Based on the survey results, the impact of the 'third-dose assumption' on national coverage estimates at 12 months of age was estimated. Of 219 surveyed children assessed as up-to-date at 12 months of age only by applying the 'third dose assumption', 212 (96.8%) met study criteria of 'definite' immunisation for all unrecorded first and second vaccine doses. Of the remaining seven, six believed all doses had been received, while one confirmed that one dose had been missed. The 'third dose assumption' overestimated coverage by 0.2 per cent, based on criteria for 'definite' immunisation. If the assumption were not used, immunisation coverage at 12 months of age in Australia would have been underestimated by 7 per cent. The 'third dose assumption' is valid and important to use in calculating immunisation coverage from the ACIR. Although ACIR reporting and coverage levels continue to improve, under-reporting of vaccine doses due at two and four months of age persists. The 'third dose assumption' may be applicable to comparable immunisation registries in other countries.

Australia↗
PubMed2003

Is low immunisation coverage in inner urban areas of Australia due to low uptake or poor notification?

INTRODUCTION: The Australian Childhood Immunisation Register (ACIR) consistently reveals pockets of lower immunisation coverage in inner urban areas. We investigated whether low uptake or poor notification of immunisation is the main reason for this difference. METHODS: We estimated under reporting by telephone surveying the parents of 640 children recorded as incompletely immunised on the ACIR at 12 months of age. Immunisation status was based on parental report of written records and/or date of receipt. RESULTS: Of the 97 children living in inner urban areas (defined by postcode and population density), 55 (57%) were shown to be 'definitely immunised'. One hundred and thirty-four (53%) of the 253 children in other urban areas were shown to be 'definitely immunised'. Both these groups were significantly more likely to be 'definitely immunised' than the 104 (36%) of 290 children in areas outside capital cities (p < 0.0001). DISCUSSION: Apparent lower immunisation uptake in inner urban areas of Australia may be attributable to reporting error.

Australia↗
PubMed2002

The epidemiology of cardiac arrests in a Sydney hospital.

AIM: To examine the epidemiology of cardiac arrest (CA) in New South Wales (NSW), Australia, and a large teaching hospital in Sydney and to identify predictors of survival. METHODS: Data from the 1996/97 NSW inpatient statistics collection were analysed. Logistic regression was used to determine predictors of mortality from CA. RESULTS: In 1996/97 in public hospitals, Eastern Sydney Area Health Service (AHS) (47.5), and in private hospitals of Macleay-Hastings District Health Services (DHSs), recorded the highest crude CA rates in NSW with figures of 47.5 and 21.3 per 10,000 hospital separations. Standardised CA rates were highest in Western Sydney, Illawara, Macleay-Hasting, Mid North Coast and Orana DHSs. Most CAs in hospital 'X' occurred after admission and 55.7% occurred in patients admitted with a non-cardiac principal diagnosis, mainly pneumonia. Acute myocardial infarction was the leading diagnosis (28.9%) in patients who suffered CA after admission. Only 32% of CA patients survived to discharge. Age above 65 (odds ratio (OR)=2.284, P=0.006) had the highest effect on cardiac mortality. The longer the patients were in the intensive care unit (OR=0.997, P=0.037), the more likely they were to survive. CONCLUSION: We describe considerable variation in CA rates in NSW. The majority of hospital CAs occur at or soon after admission, and are associated with underlying non-cardiac conditions. Survival following hospital CA is low, but there may be preventable elements. Knowledge of risk factors and epidemiology of hospital CAs may help identify patients at risk of CA.

Adult↗
PubMed2002

Hospital in the home is cost saving for appropriately selected patients: a comparison with in-hospital care.

BACKGROUND: As the cost of acute care in hospitals increases, there is an increasing need to find alternative means of providing acute care. Hospital in the home (HITH) has developed in response to this challenge. Current evidence is conflicting as to whether HITH provides cost savings compared with in-hospital care (IHC). The heterogeneous nature of HITH and the clinical complexity of patients is the greatest obstacle to making valid comparisons between the two modes of care. OBJECTIVE: To compare costs and outcomes of HITH to IHC in hospitals in Victoria, Australia. DATA SOURCES/STUDY SETTING: Hospital morbidity data and medical records from Victoria, Australia. STUDY DESIGN: A costing study of 924 randomly selected episodes of HITH care, individually matched to 924 comparable IHC episodes. METHODS: Unadjusted total episode costs (TEC) and averaged daily costs for HITH and IHC were calculated. Mortality and length of stay (LOS) were compared for HITH and IHC episodes. Simple linear and multiple regression were used to analyse costing data, while logistic regression was used to compare in-hospital mortality and LOS in HITH versus IHC episodes. PRINCIPAL FINDINGS: The 1848 episodes of care in the sample represented a heterogeneous range of acute conditions in 31 Victoria hospitals. HITH consisted of two distinct subgroups: pure-HITH (total episode substitution) and mixed-HITH (partial episode substitution). The cost of episodes of acute care containing a HITH component were overall 9% less expensive than IHC (P = 0.04), while pure-HITH was 38% cheaper than matched IHC (P < 0.001). The variable HITH, along with LOS and chemotherapy, explained the 60% variation in TEC. The mean cost of pure-HITH episodes was 22% lower compared to mixed-HITH (P = 0.004). The in-hospital mortality rate in HITH (3.8%) and IHC (5.2%) was not significantly different. Pure-HITH was associated with shorter LOS, while mixed HITH was strongly associated with longer LOS. CONCLUSION: In our study the adjusted cost of HITH was significantly cheaper than IHC, particularly as total episode substitution. The cost needs to be adjusted because many factors other than HITH or IHC can influence crude costs. There may be potential for wider use of HITH for appropriately selected patients.

Acute Disease↗